How to slow aging: the science of reversing cellular decline

01 The Hallmarks of Aging

Aging was once considered an inevitable, unstructured process, a gradual wearing down of the body like a machine wearing out. But in 2013, researchers proposed a framework that transformed how science understands aging: the hallmarks of aging. These are the cellular and molecular processes that collectively drive the deterioration we experience as we grow older. Understanding them opened the door to targeting each one therapeutically.

The hallmarks include genomic instability, the accumulation of DNA damage from radiation, chemicals, and replication errors; telomere attrition, the shortening of protective caps at chromosome ends that limits how many times a cell can divide; epigenetic alterations, changes in gene expression patterns that accumulate with age; loss of proteostasis, the failure of cellular machinery that folds and maintains proteins; mitochondrial dysfunction, declining energy production in cellular powerhouses; and cellular senescence, the accumulation of zombie cells that stop dividing but refuse to die, secreting inflammatory signals that damage surrounding tissue.

Later additions include stem cell exhaustion, altered intercellular communication, and chronic low-grade inflammation (inflammaging). Each hallmark is a potential intervention point. If aging is not a single process but a collection of underlying mechanisms, then targeting those mechanisms individually could slow or even reverse aspects of aging.

02 Caloric Restriction: The Gold Standard

Of all interventions shown to extend lifespan, caloric restriction (CR) has the strongest evidence base. In laboratory settings, reducing caloric intake by 20 to 40 percent while maintaining adequate nutrition extends lifespan in yeast, worms, flies, mice, and rats. Some studies have shown lifespan extensions of 30 to 50 percent in rodents. The effect appears to work by activating cellular stress responses and repair mechanisms that are normally dormant when nutrients are abundant.

Caloric restriction triggers a cascade of molecular events. It activates AMPK, an energy sensor that promotes autophagy, the cellular recycling process that clears damaged components. It inhibits mTOR, a nutrient-sensing pathway that, when overactive, accelerates aging. It increases sirtuins, proteins that promote DNA repair and mitochondrial health. These pathways represent some of the most promising drug targets in aging research.

Whether CR works in humans remains an open question. Long-term human studies are challenging because adherence is difficult and human lifespans are long enough that studying the endpoint takes decades. The CALERIE trial, a two-year study of caloric restriction in non-obese adults, showed improvements in metabolic health markers but was too short to measure effects on lifespan. Most researchers believe that the benefits of CR in humans are real but smaller than in mice, and that mimicking its effects with drugs may be more practical than sustaining a restrictive diet.

03 Senolytics: Clearing Zombie Cells

Cellular senescence is one of the most exciting targets in aging research. Senescent cells are cells that have stopped dividing but resist apoptosis, the normal programmed cell death. They accumulate with age and secrete a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype (SASP), which damages nearby healthy cells and promotes tissue dysfunction. In mice, clearing senescent cells extends healthspan by up to 25 percent.

Senolytics are drugs that selectively kill senescent cells. The first senolytic combination, dasatinib (a leukemia drug) plus quercetin (a plant flavonoid), was shown in 2015 to selectively eliminate senescent cells in culture and improve physical function in aged mice. Since then, numerous senolytic compounds have been identified, including fisetin, navitoclax, and combinations of various drugs. Early human trials are underway for conditions including osteoarthritis, chronic kidney disease, and Alzheimer's disease.

The distinction between lifespan (total years lived) and healthspan (years lived in good health) is crucial. Extending lifespan without extending healthspan would mean more years of disease and disability. Senolytics aim to compress morbidity, allowing people to live healthier for longer and to spend less time in decline. A drug that extends healthspan by five years, even if it does not extend lifespan at all, would be transformative for public health.

04 mTOR, Rapamycin, and the Drug Pipeline

Rapamycin, a compound discovered in soil from Easter Island, is perhaps the most promising anti-aging drug candidate. It works by inhibiting mTOR, a protein that acts as a nutrient sensor, telling cells to grow when food is abundant. By inhibiting mTOR, rapamycin tricks cells into a state resembling caloric restriction, activating repair and recycling processes.

In mice, rapamycin extends lifespan by 14 to 26 percent, even when started late in life. It is already an FDA-approved drug used in organ transplantation and as a coating on cardiac stents. The major question is whether chronic mTOR inhibition can be tolerated in humans for long enough to matter. Side effects include immunosuppression, impaired wound healing, and metabolic changes. Newer mTOR inhibitors and dosing strategies aim to capture the benefits while minimizing side effects.

Other compounds in the pipeline include NAD+ precursors (NMN and NR) that boost levels of a crucial cellular cofactor involved in energy metabolism and DNA repair; metformin, a diabetes drug that may slow aging through AMPK activation; and sirtuin activators that target the same pathways activated by caloric restriction. The TAME (Targeting Aging with Metformin) trial, if funded, would be the first clinical trial designed to test an anti-aging drug in humans using aging-related outcomes rather than a single disease endpoint.

05 Epigenetic Reprogramming

Perhaps the most revolutionary development in aging research is cellular reprogramming. In 2006, Shinya Yamanaka discovered that introducing four specific transcription factors (now called Yamanaka factors) could reprogram adult cells back to embryonic stem cells. This discovery, which earned a Nobel Prize, raised a tantalizing question: could partial reprogramming rejuvenate aged cells without fully reverting them to stem cells?

In 2016, researchers at the Salk Institute showed that partial reprogramming, applying Yamanaka factors for short periods, could reverse signs of aging in mice without causing tumors. Subsequent studies have demonstrated that partial reprogramming can extend lifespan in progeria mice and rejuvenate damaged tissues. The technology is being developed by companies including Altos Labs, which launched with $3 billion in funding, and Life Biosciences.

Epigenetic reprogramming is still in its early stages. The challenge is delivering the factors safely to specific tissues without causing uncontrolled cell proliferation or cancer. But the principle is profound: if aging is partly an epigenetic pattern that can be reset, then aging itself may be more reversible than previously believed.

06 What Actually Works Today

While experimental therapies remain years from clinical use, several interventions have solid evidence for improving healthspan. Exercise is the most powerful known intervention, reducing all-cause mortality by up to 30 percent and improving cognitive function, cardiovascular health, and metabolic fitness. Even moderate exercise, 150 minutes per week, has measurable effects on cellular aging markers.

Diet quality matters as much as caloric intake. Mediterranean and plant-based diets are associated with reduced inflammation and longer telomeres. Sleep is critical for clearing cellular waste from the brain via the glymphatic system, and chronic sleep deprivation accelerates multiple aging hallmarks. Stress management reduces chronic inflammation and cortisol exposure, both of which accelerate telomere shortening.

For now, the best anti-aging strategy remains frustratingly simple: eat well, move regularly, sleep deeply, and maintain social connections. The drugs and therapies in development may one day add to this foundation, but they are unlikely to replace it. The goal of aging research is not immortality but to compress morbidity, allowing people to live vibrant, healthy lives for as long as possible.